Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pharmexa confirms progress for GV1001 trials

Pharmexa confirms progress for GV1001 trials

10th October 2007

Pharmexa has confirmed that it has seen good progress in the four clinical trials of GV1001, a peptide vaccine which activates the patients’ immune system – primarily the T-cells – to recognise and kill cancer cells.

The trials include PrimoVax and Telovac phase III trials, a HeptoVax phase II trial as well as a small investigator sponsored trial of GV1001 in Non-Small Cell Lung Cancer (NSCLC) patients.

The PrimoVax trial, looking at GV1001 in non-resectable pancreatic cancer patients, has seen a positive enrolment rate with the expectation to see all 520 patients recruited by quarter three of 2008.

The Telovac phase III trial of GV1001 in non-resectable pancreatic cancer patients has welcomed a delegation of British investigators and staff to co-ordinate it as well as many British cancer doctors expressing their interest and enthusiasm in the trial’s developments.

Also the HeptoVax trial is close to being fully enrolled and is just one patient from reaching the planned 41 patients. The trial takes place in three centres in Spain, France and Germany.

Pharmexa is a biotechnology company working in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.